Search PubMed⌕ Search

Biomedical subjects

R S Koff

Publications and source records attributed to R S Koff.

148 records · Page 9Linked to original sources
PubMedDate not supplied

A comparison of bumetanide and furosemide in the treatment of ascites. Cooperative study.

In a cooperative study by clinicians in three medical facilities, bumetanide was compared with furosemide in patients presenting with ascites, a complication of chronic liver disease. In an open, parallel, randomized trial, 43 patients received bumetanide and 16 patients received furosemide. They were treated for from one to 28 weeks. Weight loss and decrease in abdominal girth following diuretic action occurred in both groups but was statistically significant only in the bumetanide treated patients. Because of the small number of patients on furosemide, valid statistical analysis could not be obtained. No evidence of hepatic encephalopathy developed during this study, and only one patient on furosemide was discontinued as a result of severe electrolyte imbalance. Differences in changes of electrolytes and uric acid ere not statistically significant in the two groups. The majority of drug-related abnormalities were the result of the pharmacologic activity of the diuretic.

Adult↗
PubMedDate not supplied

The effects of a single, intravenous dose of bumetanide versus furosemide in patients with ascites and edema due to alcoholic liver disease.

Ascites with or without edema, secondary to alcoholic liver disease, which had failed to respond to conventional in-hospital medical treatment with thiazides, spironolactone, and salt restriction was treated with a single intravenous dose of 0.5 mg bumetanide or 20 mg furosemide. In this single-blind, randomized, parallel study in 20 men over 18 years of age, significant diuresis and increased excretion of sodium, potassium, and chloride occurred with both drugs. Weight loss was slight but significant within groups but not between drug treatments. Osmolality was significantly decreased after both treatments due to the magnitude of urine volume. Sodium/potassium ratio was significantly increased up to 120 minutes after both treatments. Creatinine excretion and clearance were increased after treatment with bumetanide but not significantly. In the furosemide group, the increase was first significant but after 90 minutes remained decreased. Supine and standing blood pressure and pulse rate changes were negligible. EKG monitoring revealed no abnormalities. No consistent alterations of laboratory tests were identified after treatment, nor were any important clinical adverse responses recognized. A 15-decibel unilateral high-frequency hearing loss was observed following bumetanide treatment in one patient with prior evidence of ear disease.

Adult↗
PubMedDate not supplied

Hepatitis B due to transfusion of mislabeled blood.

Transfusion of a misidentified and mislabeled unit of hepatitis B surface antigen (HBsAg)-positive blood was recognized 18 hours after the transfusion episode. Within 24 hours of transfusion the recipient became HBsAg-positive, and antibody to the hepatitis B core antigen (anti-HBc) was detected. Despite hepatitis B immune globulin (HBIG) administration of 28 hours after transfusion, the serologic markers persisted for at least one month. Clinically apparent hepatitis developed about two months after transfusion. At this time HBsAg could not be detected, but antibody to HBsAg (anti-HBs) was present and anti-HBc persisted. The recipient recovered and became a plasmapheresis donor for several hepatitis B research programs.

Aged↗